Author: News Room

ST. JOHN’S, Newfoundland and Labrador, March 30, 2026 (GLOBE NEWSWIRE) — Kraken Robotics Inc. (“Kraken” or the “Company”) (TSX-V: PNG, OTCQB: KRKNF), is pleased to announce the appointment of Don Robertson to its Board of Directors and the promotion of John Salama to the role of Chief Information Officer, effective immediately. Don Robertson Appointed to Board of Directors Mr. Robertson brings more than 30 years of experience in corporate finance, mergers and acquisitions (M&A), and public company governance. He has advised boards of directors and senior management teams on a wide range of strategic matters, including M&A, divestitures, joint ventures,…

Dublin, March 30, 2026 (GLOBE NEWSWIRE) — The “Advanced Melanoma Market Report 2026” has been added to ResearchAndMarkets.com’s offering. The advanced melanoma market has demonstrated robust growth, expanding from $4.12 billion in 2025 to a projected $4.5 billion in 2026, registering a CAGR of 9.3%. This surge is primarily driven by a lack of treatment options in advanced stages, rising melanoma incidence, and enhanced hospital infrastructure. Increased adoption of chemotherapy and biological therapies also play crucial roles. Looking ahead, the market is poised to reach $6.37 billion by 2030, maintaining a CAGR of 9.1%. Key factors contributing to this growth…

Dublin, March 30, 2026 (GLOBE NEWSWIRE) — The “PD-1 Resistant Head and Neck Cancer Market Report 2026” has been added to ResearchAndMarkets.com’s offering. The PD-1 resistant head and neck cancer market is experiencing substantial growth, forecasted to rise from $1.43 billion in 2025 to $2.41 billion by 2030 at an impressive compound annual growth rate (CAGR) of 11%. This growth is driven by increased investment in immuno-oncology research, enhanced adoption of combination therapy strategies, and escalating use of genomic profiling for personalized treatments. The collaboration between pharmaceutical and biotech firms is fostering rapid advancements in treatment modalities, particularly in early…

VANCOUVER, British Columbia, March 30, 2026 (GLOBE NEWSWIRE) — Equinox Gold Corp. (TSX: EQX, NYSE American: EQX) (“Equinox Gold” or the “Company”) is pleased to report results from updated technical reports for its Greenstone Gold Mine (“Greenstone”) located in Ontario, Canada and its Valentine Gold Mine (“Valentine”) located in Newfoundland & Labrador, Canada. In addition, the Company today reported its Mineral Reserves and Mineral Resources as at December 31, 2025, including 19 million ounces of gold in Mineral Reserves, 19 million ounces in Measured and Indicated Mineral Resources exclusive of Mineral Reserves, and 11 million ounces in Inferred Mineral Resources. For…

Dublin, March 30, 2026 (GLOBE NEWSWIRE) — The “Cutaneous Squamous Cell Carcinoma (cSCC) Market Report 2026” has been added to ResearchAndMarkets.com’s offering. The cutaneous squamous cell carcinoma (cSCC) market is set for notable expansion, with the market size anticipated to increase from $7.87 billion in 2025 to $8.33 billion in 2026, at a CAGR of 5.8%. Continued growth is projected to peak at $10.35 billion by 2030, indicating a CAGR of 5.6%. This trend is driven by advancements in diagnostics, growing adoption of outpatient procedures, and the rising establishment of dermatologic oncology centers, along with improved access to early detection…

Dublin, March 30, 2026 (GLOBE NEWSWIRE) — The “Carcinoid Tumor Market Report 2026” has been added to ResearchAndMarkets.com’s offering.The global carcinoid tumor market is rapidly expanding, with projections showing it will surge from $1.77 billion in 2025 to $1.96 billion in 2026, achieving a CAGR of 10.5%. By 2030, the market is expected to reach $2.88 billion, driven by an increased focus on rare cancer treatments, advanced oncology care facilities, and novel therapies. Enhanced neuroendocrine tumor research and growing availability of somatostatin analog treatments are critical factors contributing to this growth. Over the forecast period, innovation in targeted therapies, precision…

Dublin, March 30, 2026 (GLOBE NEWSWIRE) — The “Bile Duct Cancer Market Report 2026” has been added to ResearchAndMarkets.com’s offering. The bile duct cancer market is witnessing robust growth, expanding from $2.59 billion in 2025 to an anticipated $2.82 billion in 2026 at a compound annual growth rate (CAGR) of 8.7%. This growth is fueled by advancements in early diagnostics, a rising incidence of liver and bile duct disorders, and the expansion of oncology treatment centers. Additionally, the increasing use of chemotherapy regimens and growing awareness of rare cancers contribute to market momentum. Looking ahead, the bile duct cancer market…

WASHINGTON, March 30, 2026 (GLOBE NEWSWIRE) — Pallas Advisors is pleased to announce that General (Ret.) Kenneth F. “Frank” McKenzie, Jr. has joined the Pallas Speakers Bureau, a platform connecting global audiences with top-tier national security experts. Following his retirement from the U.S. Marine Corps in 2022, General McKenzie has served as Executive Director of the Global and National Security Institute and Cyber Florida at the University of South Florida. He has also been named the 21st President of The Citadel, beginning in July 2026. General McKenzie brings decades of experience leading large, complex organizations in high-pressure, rapidly evolving environments.…

VICTORIA, Seychelles, March 30, 2026 (GLOBE NEWSWIRE) — MEXC, the world’s fastest-growing digital asset exchange and a pioneer of true zero-fee trading, has listed the twelfth batch of Ondo tokenized stock trading pairs on its spot market, as part of its ongoing collaboration with Ondo Finance. The batch comprises 20 new pairs, all available to trade with zero fees for the first 30 days. The new pairs were introduced across two listing dates. The first ten went live on March 27, 2026, and the remaining ten on March 30, 2026. The batch includes AXPON/USDT, SBUXON/USDT, AMGNON/USDT, NEMON/USDT, and VRTXON/USDT, among…

Dublin, March 30, 2026 (GLOBE NEWSWIRE) — The “Pancreatic Adenocarcinoma Treatment Market Report 2026” has been added to ResearchAndMarkets.com’s offering. The pancreatic adenocarcinoma treatment market is witnessing remarkable growth, projected to expand from $2.41 billion in 2025 to $2.73 billion in 2026 at a 13.3% CAGR. This escalation is rooted in limited treatment alternatives, reliance on traditional chemotherapy, low early-stage diagnosis, and hospital-centric treatment approaches. Looking ahead, the market is expected to soar to $4.45 billion by 2030, driven by personalized targeted therapies, the rising use of monoclonal antibodies and immunotherapies, digital health solutions, and combination therapy protocols. Increasing incidences…